Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 468

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 468
---
,976

        $
        78.66

      The weighted-average grant date fair value per share of stock options granted during the years ended December 31, 2024, 2023 and 2022 was $67.31, $70.94 and $48.82, respectively.  

        Weighted-Average

        Aggregate

        Remaining

        Intrinsic Value

        Contractual

        (in thousands)

        Life (Years)

        Options outstanding at December 31, 2024
         
        $
        425,039

        4.8

        Options exercisable at December 31, 2024
         
        $
        307,232

        4.4

        Options vested and expected to vest at December 31, 2024
         
        $
        423,367

        4.7

       The following table summarizes the Company’s shares vested and stock options exercised for each of the periods indicated: 

        For the Year Ended December 31,

        2024

        2023

        2022

        (in thousands)

        Aggregate grant date fair value of shares vested
         
        $
        147,631

        $
        142,692

        $
        140,889

        Aggregate intrinsic value of stock options exercised
         
        $
        57,158

        $
        29,711

        $
        12,150

       Grant Modification In June 2017, the Company granted its CEO 3,300,000 options with service and market conditions which were subject to a five-year cliff vesting schedule. On April 19, 2022 (the “Effective Date”), the Company entered into an agreement with its CEO to modify the vesting conditions of the options (the “Amendment”). Under the Amendment, one-third of the options vested (the “Vested Tranche”) on the Effective Date with no required service or market conditions. Subject to the CEO's continued service through each applicable vesting date and the compound annual growth rate of the Company's common stock exceeding that of the Nasdaq Biotech Index in varying percentages, the remaining two-thirds of the options (the “Unvested Tranche”) shall vest in varying increments at any time between the Effective Date and June 26, 2025 (the “Measurement Period”) when (and if) the average of the closing price of the Company’s common stock